Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Screening for prostate cancer: early detection or overdetection?

Vickers AJ, Roobol MJ, Lilja H.

Annu Rev Med. 2012;63:161-70. doi: 10.1146/annurev-med-050710-134421. Epub 2011 Nov 3. Review.

2.

Overdetection in screening for prostate cancer.

Hugosson J, Carlsson S.

Curr Opin Urol. 2014 May;24(3):256-63. doi: 10.1097/MOU.0000000000000054. Review.

PMID:
24670870
4.

Screening for prostate cancer.

Ilic D, Neuberger MM, Djulbegovic M, Dahm P.

Cochrane Database Syst Rev. 2013 Jan 31;(1):CD004720. doi: 10.1002/14651858.CD004720.pub3. Review.

PMID:
23440794
5.

PSA-based screening for prostate cancer. Too many adverse effects.

[No authors listed]

Prescrire Int. 2012 Sep;21(130):215-7. Review.

PMID:
23016259
6.

Should prostate-specific antigen screening be offered to asymptomatic men?

van Vugt HA, Bangma CH, Roobol MJ.

Expert Rev Anticancer Ther. 2010 Jul;10(7):1043-53. doi: 10.1586/era.10.64. Review.

PMID:
20645694
7.

Prostate-specific antigen levels in the United States: implications of various definitions for abnormal.

Welch HG, Schwartz LM, Woloshin S.

J Natl Cancer Inst. 2005 Aug 3;97(15):1132-7.

PMID:
16077071
8.

Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.

Carlsson S, Assel M, Sjoberg D, Ulmert D, Hugosson J, Lilja H, Vickers A.

BMJ. 2014 Mar 28;348:g2296. doi: 10.1136/bmj.g2296.

9.

Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and Ovary cancer trial.

de Koning HJ, Auvinen A, Berenguer Sanchez A, Calais da Silva F, Ciatto S, Denis L, Gohagan JK, Hakama M, Hugosson J, Kranse R, Nelen V, Prorok PC, Schröder FH; European Randomized Screening for Prostate Cancer (ERSPC) Trial; International Prostate Cancer Screening Trials Evaluation Group.

Int J Cancer. 2002 Jan 10;97(2):237-44.

10.

Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.

Schröder FH, Bangma CH, Roobol MJ.

Eur Urol. 2008 May;53(5):901-8. doi: 10.1016/j.eururo.2008.01.048. Epub 2008 Jan 28.

PMID:
18262712
11.

Radical retropubic prostatectomy in men younger than 45 years diagnosed during early prostate cancer detection program.

Varkarakis J, Pinggera GM, Sebe P, Berger A, Bartsch G, Horninger W.

Urology. 2004 Feb;63(2):337-41.

PMID:
14972485
12.

Prostate-specific antigen-based screening for prostate cancer: evidence, controversies and future perspectives.

Ito K.

Int J Urol. 2009 May;16(5):458-64. doi: 10.1111/j.1442-2042.2009.02293.x. Epub 2009 Apr 1. Review.

13.

The Cost-Effectiveness of Prostate Cancer Detection with the Use of Prostate Health Index.

Heijnsdijk EA, Denham D, de Koning HJ.

Value Health. 2016 Mar-Apr;19(2):153-7. doi: 10.1016/j.jval.2015.12.002. Epub 2016 Jan 14.

14.

Landmarks in prostate cancer screening.

Schröder FH.

BJU Int. 2012 Oct;110 Suppl 1:3-7. doi: 10.1111/j.1464-410X.2012.011428.x. Review.

15.

Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force.

Lin K, Lipsitz R, Miller T, Janakiraman S; U.S. Preventive Services Task Force.

Ann Intern Med. 2008 Aug 5;149(3):192-9. Review.

PMID:
18678846
16.

Diagnosis, management and screening of early localised prostate cancer.

Selley S, Donovan J, Faulkner A, Coast J, Gillatt D.

Health Technol Assess. 1997;1(2):i, 1-96. Review.

17.

Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).

Schröder FH.

Can J Urol. 2005 Feb;12 Suppl 1:2-6; discussion 92-3. Review.

PMID:
15780157
18.

Initial management of prostate-specific antigen-detected, low-risk prostate cancer and the risk of death from prostate cancer.

Aizer AA, Chen MH, Hattangadi J, D'Amico AV.

BJU Int. 2014 Jan;113(1):43-50. doi: 10.1111/j.1464-410X.2012.11789.x. Epub 2013 Mar 8.

19.

Overdiagnosis and overtreatment of early detected prostate cancer.

Bangma CH, Roemeling S, Schröder FH.

World J Urol. 2007 Mar;25(1):3-9. Epub 2007 Feb 14. Review.

20.

Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam.

Carlsson S, Maschino A, Schröder F, Bangma C, Steyerberg EW, van der Kwast T, van Leenders G, Vickers A, Lilja H, Roobol MJ.

Eur Urol. 2013 Nov;64(5):693-9. doi: 10.1016/j.eururo.2013.04.040. Epub 2013 May 2.

Supplemental Content

Support Center